PCI's $1B Bet to Fortify US Drug Manufacturing

PHILADELPHIA, PA – April 27, 2026 – In a move poised to reshape the American pharmaceutical landscape, PCI Pharma Services has announced a series of major infrastructure investments exceeding $1 billion globally, with a significant portion dedicated to expanding its sterile drug manufacturing and advanced delivery capabilities within the United States. The initiative, highlighted by a new $100 million facility in San Diego, directly addresses the nation’s urgent call for a more resilient domestic supply chain while positioning the company to meet the surging demand for complex biologic therapies.

This strategic expansion by the global contract development and manufacturing organization (CDMO) is not merely about adding capacity; it represents a calculated bet on the future of medicine, where advanced therapies require equally advanced production infrastructure. As the industry grapples with the lessons learned from recent global disruptions, PCI's investment signals a pivotal shift toward securing the production of life-changing medicines on American soil.

Bolstering America's Pharmaceutical Backbone

The push to strengthen domestic pharmaceutical supply chains has become a cornerstone of US national health security strategy. Following the vulnerabilities exposed during the COVID-19 pandemic, initiatives like the Biden-Harris administration's Executive Order 14017 have aimed to reduce reliance on foreign manufacturing for essential medicines. PCI's expansion aligns directly with these national objectives, providing tangible infrastructure to mitigate the risks of drug shortages and geopolitical instability.

By significantly increasing its US-based sterile fill-finish capacity—the critical final step in producing injectable drugs—the company is helping to build a more robust pharmaceutical ecosystem. The global sterile fill-finish market is projected to grow from $1.12 billion in 2024 to over $2 billion by 2032, driven by the explosive growth in biologics like monoclonal antibodies, mRNA vaccines, and cell therapies. More than a quarter of pharmaceutical developers now outsource these complex fill-finish processes, seeking partners with the specialized expertise and infrastructure that PCI is now scaling up.

The new and upgraded facilities in San Diego, California, and Bedford, New Hampshire, are designed to handle these next-generation treatments, from clinical trials through to large-scale commercial supply. This onshore capacity is crucial not only for ensuring a steady supply for American patients but also for fostering domestic innovation and creating highly skilled manufacturing jobs.

The Technological Edge in Advanced Drug Production

At the heart of PCI's expansion is a commitment to cutting-edge manufacturing technology. The planned $100 million project at its San Diego campus will introduce a high-speed isolator filling line for ready-to-use (RTU) syringes and cartridges. Scheduled to be operational in the first half of 2028, this addition will more than double the site's current capacity for these increasingly popular drug delivery formats.

Isolator technology represents the gold standard in aseptic manufacturing. By creating a completely sealed and sterile environment, these systems provide a superior level of contamination control compared to traditional cleanrooms. This is particularly vital for sensitive and high-value biologics, which can be easily compromised. Furthermore, isolators enhance operator safety when handling highly potent compounds, such as those used in oncology treatments.

Meanwhile, PCI's Bedford campus is commissioning a state-of-the-art isolator vial and lyophilization (freeze-drying) line capable of producing up to 33 million vials annually at a rate of 400 units per minute. This massive capacity is complemented by a new, customer-dedicated high-potent sterile fill-finish line, described as one of a kind in the US. To ensure the integrity of these products, both the San Diego and Bedford sites are being equipped with advanced automated visual inspection (AVI) systems, which can meticulously scan over 70 million syringes and cartridges and 40 million vials each year for defects, far exceeding the consistency of human inspection.

Meeting Demand for Modern Drug Delivery

The investment extends beyond sterile liquid filling to encompass the assembly of advanced drug-device combination products. As treatments for chronic conditions like diabetes and autoimmune disorders shift from the clinic to the home, patient-friendly delivery systems like autoinjectors have become essential. PCI is significantly bolstering its capacity in this area at its campuses in Philadelphia, Pennsylvania, and Rockford, Illinois.

Through a phased rollout over the next six months, upgrades to its assembly infrastructure will dramatically increase scale. By 2027, the addition of a third autoinjector line will bring PCI's total US capacity for autoinjector and device assembly to more than 250 million units per year. These lines feature flexible, multi-device tooling technology, allowing for the high-speed assembly of a wide variety of device platforms.

This integrated capability—combining drug filling with device assembly and final packaging—streamlines a complex supply chain for pharmaceutical clients. It enables faster speed-to-market and provides a single, accountable partner for bringing a sophisticated combination product from development to patients' hands. The expansions in Philadelphia and Rockford, which also serve as PCI's US Packaging Centers of Excellence, include substantial cold chain storage, a critical requirement for many temperature-sensitive biologic drugs.

A Strategic Play in a Booming Market

PCI's multi-year, billion-dollar investment is a clear strategic move to capture a dominant position in the high-growth CDMO market. With the pharmaceutical industry increasingly outsourcing complex manufacturing to focus on core R&D, specialized CDMOs have become indispensable partners. PCI is positioning itself not just as a contract manufacturer, but as an integrated end-to-end solutions provider.

"The pharmaceutical industry is at an inflection point, with manufacturers seeking trusted US-based partners to provide scale, expedience, and established quality and compliance track records," said Salim Haffar, CEO of PCI Pharma Services. "Backed by over $1 billion in global infrastructure investment and decades of operational expertise, PCI’s multi-year journey to bolster its domestic manufacturing footprint allows us to meet growing customer demand for innovative drug product and drug delivery solutions."

This vision is further supported by the establishment of new Pharmaceutical Development Centers of Excellence in Bedford, New Hampshire, and León, Spain. These centers, coming online in May and June respectively, will offer clients early-stage support in formulation, lyophilization cycle development, and analytical services. By integrating development with clinical and commercial manufacturing, PCI aims to create a seamless pathway that accelerates the entire drug lifecycle. This holistic approach is designed to attract both emerging biotech firms and established pharmaceutical giants looking to de-risk their supply chains and expedite the delivery of their most innovative therapies to patients worldwide.